Legal News

A question was posed to students of a pharmacy ethics class. In every case, the answers given by the students were different from the responses of the practicing pharmacists.

The Office of the Inspector General found that CMS reimbursed plan sponsors $43.3 million for prescription drugs on the market that FDA classifies as less than effective.

As the nation rolls out the new healthcare reform law, the National Association of Chain Drug Stores is urging more recognition for the role of pharmacists in medication adherence.

FDA has determined to significantly restrict the use of formulations that contain rosiglitazone (Avandia, Avandamet, and Avandaryl, GlaxoSmithKline) to patients with Type 2 diabetes who cannot control their diabetes with other medications.

Pharmacies soon may be stocking their shelves with laboratory-developed tests that first require FDA approval.

Abbott is complying with FDA's request to withdraw sibutramine (Meridia) from the U.S. market because the obesity drug may pose unnecessary cardiovascular (CV) risks to patients.

The DEA has changed its policy and now recognizes long-term-care nurses as agents of prescribers of Schedule C-III through C-V medications, according to a Federal Register notice released today.

Underlying a recent FDA-hosted public meeting and workshop was the question of how FDA as a regulatory agency should increase its current oversight of clinical laboratories, specifically those developing genetic tests that may be offered at their own facilities or made available through direct-to-consumer channels.

Thirty-nine states now have a tool to help pharmacists identify at least some questionable prescriptions and suggest when a patient may be doctor-shopping or pharmacy-shopping in order to obtain controlled substances. That tool is the state prescription monitoring program.

A Congressional bill aims to boost the capacity for information exchange among state programs that monitor prescription controlled substances and seeks to provide continued grant funding to support such efforts.

Collaborative practice agreements between physicians and pharmacists will be a reality in Pennsylvania within the next couple of years.

The Washington State Board of Pharmacy is revisiting its rules requiring pharmacists to dispense emergency contraceptives.

Use of bar-code technology is widespread in the general retail environment. Its advantages have not yet been fully exploited in the hospital and community-pharmacy settings.

The 2,400-page healthcare reform bill included language establishing the Patient Centered Outcomes Research Institute, a group grounded in the tenets of comparative effectiveness research. Its mission is significant, but whether it has the power to effect change remains to be seen.

Although the Patient Protection and Affordable Care Act (PPACA) creates an abbreviated approval pathway for biological products that are demonstrated to be ?highly similar? (biosimilar) to or ?interchangeable? with an FDA-approved biological product, only time will tell how long it will take for these biosimilars to reach the marketplace.

Sens. Kay R. Hagan (D-N.C.) and Al Franken (D-Minn.) have introduced The Medication Therapy Management (MTM) Expanded Benefits Act, a bill that will allow seniors with one chronic illness to thoroughly review all their medications with a pharmacist in a one-on-one session.

The Drug Enforcement Administration has released its long-awaited interim final rule for electronic prescribing of controlled substances.

A ballot initiative moving toward approval in North Dakota could open the doors to chain pharmacy in the state.

The relationship between prescribing practitioners and nurses working in a long-term-care (LTC) facility is of significant concern to the LTC facility when controlled substances are needed.

As Americans increasingly turn to vitamins and herbal supplements as alternatives to prescription drug use, medical professionals and government leaders worry that few realize the implications.

Oregon's law requiring prescriptions for pseudoephedrine products practically eliminated its illicit methamphetamine problem. But some pharmacists, consumer groups, and the drug industry say that it will increase healthcare costs and inconvenience consumers. They think electronic sales-tracking systems would be a better approach.

The promise of personalized medicine is approaching realization. As more medications are developed, pharmacists will be on the front line of individualized prescribing based upon genome-based diagnostic tests.

The healthcare reform legislation signed into law March 23 is expected to give healthcare access to 32 million Americans who are currently uninsured. The legislation gives pharmacists a role in helping alleviate the influx of new patients.

The continuing debate over healthcare reform keeps the subject of medication adherence in the public eye. For pharmacy, says NACDS, the issue is a top priority.

Pharmacies can enhance their continuous quality improvement program results by working on three critical elements: implementation, training, and monitoring.

Both the FTC?s consumer protection and competition bureaus are spearheading an investigation into CVS Caremark?s alleged monopolistic practices. HHS is investigating possible false Medicare claims. DEA is investigating charges of improper sale of pseudoephedrine in 2007 and 2008. And the SEC has received complaints of insider trading.

An overview of several provisions of "The Patient Protection and Affordable Care Act" affecting pharmacies and pharmacy practice.

A pharmacist's most important job is to see that the right drug in the right strength with the right label reaches the right patients.